Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
August 10, 2015 11:34 AM EDT
Stifel analyst Thomas Shrader reiterated a Buy rating and $19 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced Q2 results and a broad partnership with MedImmune to develop INO-3112 in combination with MedImmunes collection of IO molecules.
Shrader said he likes the deal.... More
August 10, 2015 11:19 AM EDT
Piper Jaffray analyst Charles Duncan reiterated his Overweight rating and $31 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced 2Q financials and a partnership with AstraZeneca worth up to $700M ($27.5M upfront + potential development, regulatory, and commercialization milestones) plus tiered double... More
August 10, 2015 6:08 AM EDT
Inovio Pharma (NASDAQ: INO) announced that it has entered into a license agreement and collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN).
Under the agreement, MedImmune will acquire exclusive rights to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for... More
